


## L-Aspartic acid-<sup>13</sup>C-1

<b>Cat. No.:</b>	HY-N0666S10
<b>CAS No.:</b>	68261-19-8
<b>Molecular Formula:</b>	C <sub>3</sub> <sup>13</sup> CH <sub>7</sub> NO <sub>4</sub>
<b>Molecular Weight:</b>	134.1
<b>Target:</b>	Endogenous Metabolite
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	L-Aspartic acid- <sup>13</sup> C-1 is the deuterium labeled L-Aspartic acid[1]. L-Aspartic acid is an amino acid, shown to be a suitable proagent for colon-specific agent delivery[2][3].
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.
- [2]. Hosoya K, et al. Blood-brain barrier produces significant efflux of L-aspartic acid but not D-aspartic acid: in vivo evidence using the brain efflux index method. *J Neurochem*. 1999 Sep;73(3):1206-11.
- [3]. Leopold CS, et al. In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery. *J Pharmacokinetic Biopharm*. 1995 Aug23(4):397-406.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA